Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro

Anticancer Research

Volumn 32, Issue 6, 2012, Pages 2249-2256

  Morisaki, Takashi ^a   Umebayashi, Masayo ^a   Kiyota, Akifumi ^a   Koya, Norihiro ^a   Tanaka, Hiroto ^a   Onishi, Hideya ^b   Katano, Mitsuo ^b  

^a Fukuoka General Cancer Clinic   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

ADCC; Cetuximab; Cholangiocarcinoma; Killer lymphocytes

Indexed keywords

CD16 ANTIGEN; CD3 ANTIBODY; CD56 ANTIGEN; CETUXIMAB; ERBITAX; IMMUNOGLOBULIN; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ARTICLE; BILE DUCT CARCINOMA; CARCINOMA CELL; CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; KILLER CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BILE DUCT TUMOR; CELL SURVIVAL; CYTOKINE INDUCED KILLER CELL; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL SURVIVAL; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE;

EID: 84864561428     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Khan SA, Toledano MB and Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10: 77-82, 2008.
2. Aljiffry M, Walsh MJ and Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 15: 4240-4262, 2009.
3. Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125, 2004.
4. Verslype C, Prenen H and Van Cutsem E: The role of chemotherapy in biliary carcinoma. HPB 10: 164-167, 2008.
5. Eckmann KR, Patel DK, Landgraf A, Slade JH, Lin E, Kaur H, Loyer E, Weatherly JM and Javie M: Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointestinal Cancer Res 4: 155-160, 2011.
6. Hezel AF and Zhu AX: Systemic therapy for biliary tract cancers. The Oncologist 13: 415-423, 2008.
7. Zografos GN, Farfaras A, Zagouri F, Chrysikos D and Karaliotas K: Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int 10: 10-20, 2011.
8. Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F and Rogler G: Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer 10: 302, 2010.
9. Jan Y-Y, Yeh T-S, Yeh J-N, Yang H-R and Chen M-F: Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma. Ann Surgery 240: 89-94, 2004.
10. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S and Shibata T: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425, 2008.
11. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S and Shibata T: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signaling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 100: 1257-1266, 2009.
12. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S and Gruenberger T: Cetuximab, gemcitabine, and oxailplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 11: 1142-1148, 2010.
13. Chau I and Cunningham D: Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 100: 1704-1719, 2009.
14. Zhang T and Herlyn D: Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother 58: 475-492, 2009.
15. Mistry AR and O'Callaghan CA: Regulation of ligands for the activating receptor NKG2D. Immunology 121: 439-447, 2007.
16. Ferris RL, Jaffee EM and Ferrone S: Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28: 4390-4399, 2010.
17. Alderson KL and Sondel PM. Clinical Cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biothecnol 2011: 1-7, 2011.
18. Parkhurst MR, Riley JP, Dudley ME and Rosenberg SA: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but dose not mediate tumor regression. Clin Cancer Res 17: 6287-6297, 2011.
19. Maréchal R, Schutter JD, Nagy N, Demetter P, Lemmers A, Devière J, Salmon I, Tejpar S and Van Laethem J-L: Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer 10: 340, 2010.
20. Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K and Mann DL: Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res 29: 134, 2010.
21. Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I and Katano M: Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res 31: 2505-2510, 2011.
22. Wang X, Cai J, Zhong H, Denham SA and Terasaki PI: Screening of high cytotoxic tumor killer cells using a sensitive adherent target detachment assay. J Immunol Methods 295: 57-65, 2004.
23. Zhou Q, Guo AL, Xu CR, An SJ, Wang Z, Yang SQ and Wu YL: A dendritic cell-based tumor vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol 153: 392-400, 2008.
24. Sandilands GP, Atrah HI, Templeton G, Cocker JE, Lucie N, Crawford RJ, and MacSween RN: In vivo and in vitro blocking of human lymphocyte Fc gamma-receptors by intravenous gammaglobulin. J Clin Lab Immunol 23: 109-115, 1987.
25. Nimmerjahn F and Ravetch JV: The anti-inflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204: 11-15, 2007
26. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S and Ferris RL: Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma. Cancer Immunol Immunother 58: 1853-1864, 2009.
27. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S and Carson III WE: The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines. Clin Cancer Res 13: 6419-6428, 2007.
28. Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, and Fujii H: Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 97: 494-501, 2007.
29. Harder J, Walz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A and Opitz OG: EGFR and Her2 expression in advanced biliary tract cancer. World J Gastroenterol 15: 4511-4517, 2009.
30. Verneris MR, Karimi M, Baker J, Jayaswal A, and Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072, 2004.
31. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L and Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 175: 7819-7828, 2005.